Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Faivre-Finn, Corinne, Snee, Michael, Ashcroft, Linda, Appel, Wiebke, Barlesi, Fabrice, Bhatnagar, Adityanarayan, Bezjak, Andrea, Cardenal, Felipe, Fournel, Pierre, Harden, Susan, Le Pechoux, Cecile, McMenemin, Rhona, Mohammed, Nazia, O'Brien, Mary, Pantarotto, Jason, Surmont, Veerle, Van Meerbeeck, Jan P, Woll, Penella J, Lorigan, Paul, Blackhall, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437/
https://www.ncbi.nlm.nih.gov/pubmed/28642008
http://dx.doi.org/10.1016/S1470-2045(17)30318-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555437/
https://www.ncbi.nlm.nih.gov/pubmed/28642008
http://dx.doi.org/10.1016/S1470-2045(17)30318-2

Ejemplares similares